Syngene International Q4 PAT down -7.97% at Rs147.80cr on higher input costs and other expenses

28 Apr 2022 , 08:43 PM

Syngene International Ltd reported 15.11% growth in total revenues yoy for the Mar-22 quarter on consolidated basis at Rs758.10cr. On a sequential basis, revenues were higher for the quarter by 18.19%.

For the full year FY22, the revenues were higher by 19.2% at Rs2,604cr. The company has a wholly owned subsidiary Syngene USA.

It operates in the single business vertical of offering contract research and manufacturing services, popularly called the CRAMS vertical in pharma. Syngene International is part of the Biocon group.

The consolidated net profit for Q4 was down -7.97% at Rs147.8cr while it was up on a sequential basis by 42.12%.

The lower profits on a yoy basis was largely on account of higher other expenses and higher cost of chemicals and other inputs needed for the core functioning of the business.

Net margins stood at 19.50% in Mar-22 quarter compared to 24.39% in Mar-21. NPM was higher sequentially compared to 16.21% in Q3.

Financial highlights for Mar-22 compared yoy and sequentially

	Syngene International
Rs in Crore	Mar-22	Mar-21	YOY	Dec-21	QOQ
Total Income (Rs cr)	₹ 758.10	₹ 658.60	15.11%	₹ 641.40	18.19%
Net Profit (Rs cr)	₹ 147.80	₹ 160.60	-7.97%	₹ 104.00	42.12%
Diluted EPS (Rs)	₹ 3.67	₹ 4.01		₹ 2.55
Net Margins	19.50%	24.39%		16.21%